ArticleAsian Pacific journal of cancer prevention : APJCP2025
Therapeutic Targeting of PARP Expression and Glycolysis Rate-Limiting Enzymes in Breast Cancer Patients.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is a heterogeneous disease characterized by diverse biochemical, histological, and clinical features. PARP1 and glycolysis rate-limiting enzymes play critical roles in cancer progression, making them promising therapeutic targets.
aimThis study aimed to evaluate the expression levels of PARP1 and key glycolytic enzymes (HK, PFK, and PK) in breast cancer patients and assess their potential as therapeutic indicators. MATERIALS AND
methodsA total of 120 participants (60 breast cancer patients and 60 healthy controls) were included in the study. Blood samples were collected to measure PARP1 expression and the levels of glycolytic enzymes using ELISA. Statistical analyses were performed to compare the two groups.
resultsPARP1 expression and glycolytic enzyme levels (HK, PFK, and PK) were significantly higher in breast cancer patients compared to healthy controls (p < 0.0001).
conclusionThe overexpression of PARP1 and key glycolytic enzymes indicates their involvement in breast cancer progression and underscores their potential as therapeutic targets and biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.